Melatonin Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Melatonin therapy involves the use of exogenous melatonin, a hormone produced by the pineal gland, to restore circadian rhythm alignment and provide neuroprotective effects. Melatonin (N-acetyl-5-methoxytryptamine) is a versatile molecule with antioxidant, anti-inflammatory, and anti-apoptotic properties that make it particularly relevant for neurodegenerative disease intervention[1][2].
Melatonin exerts multiple neuroprotective effects:
Clinical trials have evaluated melatonin for sleep disturbances in AD and PD, with mixed but generally positive results for improving sleep quality and certain cognitive outcomes[3][4].
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced by the pineal gland that regulates circadian rhythm and sleep-wake cycles. It has attracted significant interest as a potential neuroprotective agent in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
| Study | N | Dose | Outcome |
|---|---|---|---|
| Singer 2003 | 50 | 3 mg | Improved sleep, no cognitive benefit |
| Wade 2014 | 80 | 2 mg | Improved sleep efficiency |
| Lin 2013 | 26 | 5-9 mg | Reduced sundowning |
The study of Melatonin Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005. ↩︎
Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease. Curr Alzheimer Res. 2010. ↩︎
Sandyk R. Pineal melatonin function in Parkinson's disease. Int J Neurosci. 1991. ↩︎
Reiter RJ, et al. Melatonin as a chronobiotic and neuroprotective agent. Adv Exp Med Biol. 2019. ↩︎